Takeda Pulls FDA Application for Expanded Use of Cancer Drug Velcade
Genetic Engineering News
Millennium: The Takeda Oncology Company has decided to withdraw its sNDA for Velcade in combination with rituximab for the treatment of relapsed follicular lymphoma, citing “business reasons.” The decision was made after further evaluation based on ...
Millennium Provides Update on sNDA for VELCADE in Relapsed Follicular LymphomaMarketWatch (press release)
Millenium, Takeda Pharma Withdraw SNDA For Relapsed Follicular Lymphoma TherapyRTT News

all 13 news articles »